232276-45-8

Upstream product

• 938195-80-3 methyl N-(2,6-dichlorobenzoyl)-L-tyrosinate 
• 358-23-6 trifluoromethylsulfonic anhydride 

Downstream Products

• 938195-81-4 methyl 4-[1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]-N-(2,6-dichlorobenzoyl)-L-phenylalaninate 
• 959991-55-0 methyl 4-(4-aminopiperidin-1-yl)-N-(2,6-dichlorobenzoyl)-L-phenylalaninate 
• 959992-69-9 methyl 4-({2-[(tert-butoxycarbonyl)(methyl)amino]quinolin-7-yl}methyl)-N-[(2,6-dichlorophenyl)carbonyl]-L-phenylalaninate 
• 232276-58-3 N-(2,6-dichlorobenzoyl)-4-[4-(1,3-dioxolan-2-yl)-2,6-dimethoxyphenyl]-L-phenylalanine methyl ester 
• 232276-67-4 N-(2,6-dichlorobenzoyl)-4-(2-cyano-thien-3-yl)-L-phenylalanine methyl ester 
• 959992-08-6 4-{(2S)-2-[(2,6-dichlorobenzoyl)amino]-3-methoxy-3-oxopropyl}benzoic acid 
• 959991-54-9 methyl 4-{4-[(tert-butoxycarbonyl)amino]piperidin-1-yl}-N-(2,6-dichlorobenzoyl)-L-phenylalaninate 

Relevant academic research and scientific papers

Rh-catalyzed aerobic oxidative cyclization of anilines, alkynes, and CO

Transition-metal-catalyzed oxidative C-H cyclization of anilines has been an attractive and powerful strategy for the efficient construction of N-heterocycles. However, primary and tertiary anilines are rarely employed in this strategy due to the relative instability with strong oxidants or the presence of three C-N bonds. We describe here a novel Rh-catalyzed C-H cyclization of a wide range of anilines with alkynes and CO, using an aerobic oxidative protocol. Particularly, the simple primary anilines and readily prepared tertiary anilines could be easily converted to quinolin-2(1H)-ones, which are high value-added, biologically significant N-heterocycles, via C-N bond cleavage.

L-PHENYLALANINE DERIVATIVES

The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.